Pharmaceutical product permissions

A searchable record of what Walter is equipped to evaluate.

Explore compositions across oral solids, oral liquids, sterile injectables, topical formats and selected specialist presentations. Use the catalogue to begin a technical and commercial discussion—not as a substitute for written facility-specific confirmation.

5,500Distinct records
21Dosage forms
407Sterile injectable records
17Therapeutic indexes

Built for portfolio teams

Move from a molecule search to a focused feasibility conversation.

The catalogue brings together composition, strength, pharmacological class, dosage form, manufacturing stream, BCS class and documented regulatory references. It also incorporates products listed in Walter’s March 2025 Injectables Manufacturing Profile. Therapeutic and pharmacological classes are practical navigation labels; final indication, regulatory position and site suitability are confirmed product by product.

Search the catalogue

Selected catalogue briefs

Explore a composition for your manufacturing brief.

Browse selected compositions by dosage form, then share the required strength, pack, quantities and target market for a product-specific feasibility review.

Search the full catalogue
Browse 26 selected composition briefs

Therapeutic index

Begin with the treatment area.

Each composition is assigned to one practical primary area for navigation. Combination products may span more than one clinical use and remain subject to product-specific review.

Searchable permissions catalogue

Find a composition, dosage form or capability route.

5,500distinct permission records

Loading full catalogue search…
Therapeutic area
Dosage-form family
Specific dosage form
Pharmacological class
Manufacturing stream
BCS classification
Confirmed CDSCO category
Drugs Rules status

24 records shown

CardiovascularPRM 2650
Dosage formTablets
Oral

Aliskiren 150 mg, Amlodipine 10 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Calcium-channel blocker + Direct renin inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class III
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 2651
Dosage formTablets
Oral

Aliskiren 150 mg, Amlodipine 5 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Calcium-channel blocker + Direct renin inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class III
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 2655
Dosage formTablets
Oral

Aliskiren 300 mg, Amlodipine 10 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Calcium-channel blocker + Direct renin inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class III
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 2656
Dosage formTablets
Oral

Aliskiren 300 mg, Amlodipine 5 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Calcium-channel blocker + Direct renin inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class III
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 2713
Dosage formTablets
Oral

Amlodipine 10 mg, Atorvastatin 10 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Calcium-channel blocker + Statin
Manufacturing stream
Non-beta-lactam
BCS class
Class II (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 2714
Dosage formTablets
Oral

Amlodipine 10 mg, Atorvastatin 20 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Calcium-channel blocker + Statin
Manufacturing stream
Non-beta-lactam
BCS class
Class II (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 2715
Dosage formTablets
Oral

Amlodipine 10 mg, Atorvastatin 40 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Calcium-channel blocker + Statin
Manufacturing stream
Non-beta-lactam
BCS class
Class II (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 2716
Dosage formTablets
Oral

Amlodipine 10 mg, Hydrochlorothiazide 12.5 mg, Valsartan 160 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Angiotensin II receptor blocker + Calcium-channel blocker + Thiazide / thiazide-like diuretic
Manufacturing stream
Non-beta-lactam
BCS class
Class II (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 2717
Dosage formTablets
Oral

Amlodipine 10 mg, Hydrochlorothiazide 25 mg, Olmesartan Medoxomil 40 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Angiotensin II receptor blocker + Calcium-channel blocker + Thiazide / thiazide-like diuretic
Manufacturing stream
Non-beta-lactam
BCS class
Class II (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 2718
Dosage formTablets
Oral

Amlodipine 10 mg, Hydrochlorothiazide 25 mg, Valsartan 160 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Angiotensin II receptor blocker + Calcium-channel blocker + Thiazide / thiazide-like diuretic
Manufacturing stream
Non-beta-lactam
BCS class
Class II (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 2719
Dosage formTablets
Oral

Amlodipine 10 mg, Hydrochlorothiazide 25 mg, Valsartan 320 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Angiotensin II receptor blocker + Calcium-channel blocker + Thiazide / thiazide-like diuretic
Manufacturing stream
Non-beta-lactam
BCS class
Class II (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 2720
Dosage formTablets
Oral

Amlodipine 10 mg, Indapamide 1.5 mg (SR)

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Calcium-channel blocker + Thiazide / thiazide-like diuretic
Manufacturing stream
Non-beta-lactam
BCS class
Class II (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 2721
Dosage formTablets
Oral

Amlodipine 10 mg, Olmesartan Medoxomil 40 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Angiotensin II receptor blocker + Calcium-channel blocker
Manufacturing stream
Non-beta-lactam
BCS class
Class II (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 2722
Dosage formTablets
Oral

Amlodipine 10 mg, Perindopril 4 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
ACE inhibitor + Calcium-channel blocker
Manufacturing stream
Non-beta-lactam
BCS class
Class III
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 2723
Dosage formTablets
Oral

Amlodipine 10 mg, Perindopril 8 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
ACE inhibitor + Calcium-channel blocker
Manufacturing stream
Non-beta-lactam
BCS class
Class III
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 2724
Dosage formTablets
Oral

Amlodipine 10 mg, Telmisartan 40 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Angiotensin II receptor blocker + Calcium-channel blocker
Manufacturing stream
Non-beta-lactam
BCS class
Class II (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 2725
Dosage formTablets
Oral

Amlodipine 10 mg, Telmisartan 80 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Angiotensin II receptor blocker + Calcium-channel blocker
Manufacturing stream
Non-beta-lactam
BCS class
Class II (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 2726
Dosage formTablets
Oral

Amlodipine 10 mg, Valsartan 160 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Angiotensin II receptor blocker + Calcium-channel blocker
Manufacturing stream
Non-beta-lactam
BCS class
Class II (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 4680
Dosage formHard-gelatin capsules
Oral

Amlodipine 2.5 mg, Benazepril 10 mg

Route
Oral
Formulation type
Hard-capsule oral solid
Pharmacological class
ACE inhibitor + Calcium-channel blocker
Manufacturing stream
Non-beta-lactam
BCS class
Class III (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 2727
Dosage formTablets
Oral

Amlodipine 2.5 mg, Bisoprolol Fumarate 5 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Beta blocker + Calcium-channel blocker
Manufacturing stream
Non-beta-lactam
BCS class
Class III (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 2728
Dosage formTablets
Oral

Amlodipine 2.5 mg, Hydrochlorothiazide 12.5 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Calcium-channel blocker + Thiazide / thiazide-like diuretic
Manufacturing stream
Non-beta-lactam
BCS class
Class III
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 2729
Dosage formTablets
Oral

Amlodipine 2.5 mg, Hydrochlorothiazide 12.5 mg, Olmesartan Medoxomil 5 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Angiotensin II receptor blocker + Calcium-channel blocker + Thiazide / thiazide-like diuretic
Manufacturing stream
Non-beta-lactam
BCS class
Class II (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 2730
Dosage formTablets
Oral

Amlodipine 2.5 mg, Hydrochlorothiazide 12.5 mg, Valsartan 80 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Angiotensin II receptor blocker + Calcium-channel blocker + Thiazide / thiazide-like diuretic
Manufacturing stream
Non-beta-lactam
BCS class
Class II (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 2731
Dosage formTablets
Oral

Amlodipine 2.5 mg, Indapamide 1.5 mg (SR)

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Calcium-channel blocker + Thiazide / thiazide-like diuretic
Manufacturing stream
Non-beta-lactam
BCS class
Class II (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Explore the product catalogue

Browse product pages by therapeutic area.

Browse compositions, strengths and dosage forms for third-party and contract manufacturing enquiries. Each product page includes its catalogue specification, manufacturing and packaging considerations, and a product-specific enquiry link. Confirm the applicable unit, documents and commercial terms with Walter.

How to read this catalogue

Permission is a starting point—not a supply commitment.

01

Therapeutic index

Primary areas provide buyer-friendly navigation. Combination products may reasonably sit across several clinical categories.

02

Facility confirmation

Current licence scope, site allocation, equipment fit and applicable segregation requirements are checked before commitment.

03

Product feasibility

Formula, strength, presentation, pack, target market, testing requirements and commercial scale are assessed together.

04

Responsible use

This B2B catalogue is not prescribing information, patient guidance or a representation that every composition is currently available for sale.

Start the conversation

Found a composition worth discussing?

Use the enquiry link on any record to carry its composition and dosage form into your manufacturing brief.

Request a quote
Quick chat on WhatsAppLet’s discuss your product